Screener
Acadia Pharmaceuticals ACAD Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Income from operations | 37,836 | 32,374 | 33,220 | 51,663 |
| Interest income, net | 7,990 | 7,243 | 16,045 | 15,144 |
| Other income | 647 | 594 | 1,189 | 1,183 |
| Income before income taxes | 46,473 | 40,211 | 50,454 | 67,990 |
| Income tax expense | 14,973 | 13,545 | 15,317 | 22,337 |
| Net income | $31,500 | $26,666 | $35,137 | $45,653 |
| Earnings per share: | ||||
| Basic | $0.18 | $0.16 | $0.21 | $0.27 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's pre-tax income?
- Acadia Pharmaceuticals (ACAD) reported pre-tax income of $46.47M in Q2 2026.
- How has Acadia Pharmaceuticals's pre-tax income changed year-over-year?
- Acadia Pharmaceuticals's pre-tax income increased by 15.6% year-over-year, from $40.21M to $46.47M.
- What is the long-term trend for Acadia Pharmaceuticals's pre-tax income?
- Over 3 years (2021 to 2025), Acadia Pharmaceuticals's pre-tax income has grown at a -6.1% compound annual growth rate (CAGR), from -$167.52M to $138.9M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about Acadia Pharmaceuticals's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude